ArticleMedical physics2025
Framework to calculate
Article in Medical physics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Monte Carlo simulations ofMedical physics · 2026Article
- PSMA-Targeted Radioligand Therapy Beyond the Post-Taxane Setting: A Review of Evidence Across the Prostate Cancer Spectrum.Cancers · 2026Review
- Evaluation of radiation damage effects of low-energy Auger and conversion electrons emitted byScientific reports · 2026Article
- Framework to calculateMedical physics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundIn the treatment of metastatic castration-resistant prostate cancer (mCRPC), the standard radionuclide PURPOSE: This Study aims to develop a comprehensive pipeline based on Monte Carlo (MC) simulations to compare the therapeutic efficacy of
methodsA 2 µm resolution cell model was constructed with a 20 µm cell, an 8 µm nucleus diameter, and a 26 µm center-to-center distance. This configuration resulted in a cellular fraction of 0.24 mL/g, in agreement with that estimated from six prostate cancer patients using CT Perfusion. The prostate time-integrated activity (TIA) in the model was estimated from a patient based on a dynamic 300 MBq
resultsThe cellular absorbed dose was higher than the macro-scale dose based on SPECT-derived TIA, by 31.3%, 15.7%, and 39.8% for
conclusionsDPKs and BECKs of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.